Zoetis (ZTS) announced that Health Canada has approved Lenivia for the alleviation of pain associated with osteoarthritis in dogs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Buy Rating on Zoetis: Strategic Initiatives and Long-term Growth Potential Amid Short-term Challenges
- Zoetis’s Strategic Launch of Innovative Monoclonal Antibodies for Osteoarthritic Pain Management
- Zoetis receives positive opinion from CVMP for Lenivia
- Zoetis Declares Q4 2025 Dividend of $0.50
- Zoetis receives conditional approval for Dectomax-CA1 injectable